-
1
-
-
65349094504
-
Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: A randomized controlled trial
-
Abraldes JG, Albillos A, Bañares R, Turnes J, González R, García- Pagán JC, Bosch J. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 136: 1651–1658, 2009. doi:10.1053/j.gastro.2009.01.043.
-
(2009)
Gastroenterology
, vol.136
, pp. 1651-1658
-
-
Abraldes, J.G.1
Albillos, A.2
Bañares, R.3
Turnes, J.4
González, R.5
García- Pagán, J.C.6
Bosch, J.7
-
2
-
-
34247568377
-
Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats
-
Abraldes JG, Rodríguez-Vilarrupla A, Graupera M, Zafra C, García- Calderó H, García-Pagán JC, Bosch J. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol 46: 1040–1046, 2007. doi:10.1016/j.jhep.2007.01.020.
-
(2007)
J Hepatol
, vol.46
, pp. 1040-1046
-
-
Abraldes, J.G.1
Rodríguez-Vilarrupla, A.2
Graupera, M.3
Zafra, C.4
García- Calderó, H.5
García-Pagán, J.C.6
Bosch, J.7
-
3
-
-
84961170459
-
Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis
-
BLEPS Study Group
-
Abraldes JG, Villanueva C, Aracil C, Turnes J, Hernandez-Guerra M, Genesca J, Rodriguez M, Castellote J, García-Pagán JC, Torres F, Calleja JL, Albillos A, Bosch J, Augustin S, Llop E, Arraez DM, Hernández Mesa G, Martinez J, Reverter E, Seijo S, Turon F, Miñana J, Buenestado J, Reñe JM, Navacués CA, Planas R, Morillas RM, Bellot P, Such J, Vergara M, Puente A, de la Pena J, Mera Calviño J, Rivas Moral L, Pavel O, Alvarado E, Ardevol A, Girbau A, Cachero A, Arnaiz JA, Berzigotti A, Pich J, Rios J, Saenz R, Millan L, Beleta H, Ramos N; BLEPS Study Group. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology 150: 1160–1170, 2016. doi:10.1053/j.gastro.2016.01.004.
-
(2016)
Gastroenterology
, vol.150
, pp. 1160-1170
-
-
Abraldes, J.G.1
Villanueva, C.2
Aracil, C.3
Turnes, J.4
Hernandez-Guerra, M.5
Genesca, J.6
Rodriguez, M.7
Castellote, J.8
García-Pagán, J.C.9
Torres, F.10
Calleja, J.L.11
Albillos, A.12
Bosch, J.13
Augustin, S.14
Llop, E.15
Arraez, D.M.16
Hernández Mesa, G.17
Martinez, J.18
Reverter, E.19
Seijo, S.20
Turon, F.21
Miñana, J.22
Buenestado, J.23
Reñe, J.M.24
Navacués, C.A.25
Planas, R.26
Morillas, R.M.27
Bellot, P.28
Such, J.29
Vergara, M.30
Puente, A.31
de la Pena, J.32
Mera Calviño, J.33
Rivas Moral, L.34
Pavel, O.35
Alvarado, E.36
Ardevol, A.37
Girbau, A.38
Cachero, A.39
Arnaiz, J.A.40
Berzigotti, A.41
Pich, J.42
Rios, J.43
Saenz, R.44
Millan, L.45
Beleta, H.46
Ramos, N.47
more..
-
4
-
-
33748452682
-
Autoimmune hepatitis triggered by statins
-
Alla V, Abraham J, Siddiqui J, Raina D, Wu GY, Chalasani NP, Bonkovsky HL. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol 40: 757–761, 2006. doi:10.1097/00004836-200609000-00018.
-
(2006)
J Clin Gastroenterol
, vol.40
, pp. 757-761
-
-
Alla, V.1
Abraham, J.2
Siddiqui, J.3
Raina, D.4
Wu, G.Y.5
Chalasani, N.P.6
Bonkovsky, H.L.7
-
5
-
-
85018781407
-
Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with portal hypertension and no-response to β-blockers: A double-blind randomized trial
-
Alvarado-Tapias E, Ardévol A, Pavel O, Montanes R, Murzi M, Oblitas Susanibar E, Poca M, Torras X, Villanueva C. Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with portal hypertension and no-response to β-blockers: a double-blind randomized trial. Hepatology 64: 74A, 2016.
-
(2016)
Hepatology
, vol.64
-
-
Alvarado-Tapias, E.1
Ardévol, A.2
Pavel, O.3
Montanes, R.4
Murzi, M.5
Oblitas Susanibar, E.6
Poca, M.7
Torras, X.8
Villanueva, C.9
-
6
-
-
44949165396
-
Fluvastatin inhibits hepatitis C replication in humans
-
Bader T, Fazili J, Madhoun M, Aston C, Hughes D, Rizvi S, Seres K, Hasan M. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 103: 1383–1389, 2008. doi:10.1111/j.1572-0241.2008.01876.x.
-
(2008)
Am J Gastroenterol
, vol.103
, pp. 1383-1389
-
-
Bader, T.1
Fazili, J.2
Madhoun, M.3
Aston, C.4
Hughes, D.5
Rizvi, S.6
Seres, K.7
Hasan, M.8
-
7
-
-
85005808117
-
Hepatotoxicity of statins and other lipid-lowering agents
-
Björnsson ES. Hepatotoxicity of statins and other lipid-lowering agents. Liver Int 37: 173–178, 2017. doi:10.1111/liv.13308.
-
(2017)
Liver Int
, vol.37
, pp. 173-178
-
-
Björnsson, E.S.1
-
8
-
-
84952066804
-
Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia
-
Blais P, Lin M, Kramer JR, El-Serag HB, Kanwal F. Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia. Dig Dis Sci 61: 1714–1720, 2016. doi:10.1007/s10620-015-4000-6.
-
(2016)
Dig Dis Sci
, vol.61
, pp. 1714-1720
-
-
Blais, P.1
Lin, M.2
Kramer, J.R.3
El-Serag, H.B.4
Kanwal, F.5
-
9
-
-
84881550708
-
Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis
-
Cash WJ, O’Neill S, O’Donnell ME, McCance DR, Young IS, McEneny J, McDougall NI, Callender ME. Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis. Liver Int 33: 1166–1174, 2013. doi:10.1111/liv.12191.
-
(2013)
Liver Int
, vol.33
, pp. 1166-1174
-
-
Cash, W.J.1
O’Neill, S.2
O’Donnell, M.E.3
McCance, D.R.4
Young, I.S.5
McEneny, J.6
McDougall, N.I.7
Callender, M.E.8
-
10
-
-
2142768218
-
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity
-
Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 126: 1287–1292, 2004. doi:10.1053/j.gastro.2004.02.015.
-
(2004)
Gastroenterology
, vol.126
, pp. 1287-1292
-
-
Chalasani, N.1
Aljadhey, H.2
Kesterson, J.3
Murray, M.D.4
Hall, S.D.5
-
11
-
-
84924910736
-
Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells
-
Chong LW, Hsu YC, Lee TF, Lin Y, Chiu YT, Yang KC, Wu JC, Huang YT. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells. BMC Gastroenterol 15: 22, 2015. doi:10.1186/s12876-015-0248-8.
-
(2015)
BMC Gastroenterol
, vol.15
, pp. 22
-
-
Chong, L.W.1
Hsu, Y.C.2
Lee, T.F.3
Lin, Y.4
Chiu, Y.T.5
Yang, K.C.6
Wu, J.C.7
Huang, Y.T.8
-
12
-
-
65449171213
-
Simvastatin protects against cholestasis-induced liver injury
-
Dold S, Laschke MW, Lavasani S, Menger MD, Jeppsson B, Thorlacius H. Simvastatin protects against cholestasis-induced liver injury. Br J Pharmacol 156: 466–474, 2009. doi:10.1111/j.1476-5381.2008.00043.x.
-
(2009)
Br J Pharmacol
, vol.156
, pp. 466-474
-
-
Dold, S.1
Laschke, M.W.2
Lavasani, S.3
Menger, M.D.4
Jeppsson, B.5
Thorlacius, H.6
-
13
-
-
84939268765
-
Statin use and non-alcoholic steatohepatitis in at risk individuals
-
Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V, Maggioni M, Kakela P, Wiklund O, Mozzi E, Grimaudo S, Kaminska D, Rametta R, Craxi A, Fargion S, Nobili V, Romeo S, Pihlajamaki J, Valenti L. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 63: 705–712, 2015. doi:10.1016/j.jhep.2015.05.006.
-
(2015)
J Hepatol
, vol.63
, pp. 705-712
-
-
Dongiovanni, P.1
Petta, S.2
Mannisto, V.3
Mancina, R.M.4
Pipitone, R.5
Karja, V.6
Maggioni, M.7
Kakela, P.8
Wiklund, O.9
Mozzi, E.10
Grimaudo, S.11
Kaminska, D.12
Rametta, R.13
Craxi, A.14
Fargion, S.15
Nobili, V.16
Romeo, S.17
Pihlajamaki, J.18
Valenti, L.19
-
14
-
-
34249342305
-
Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: A histopathological follow-up study
-
Ekstedt M, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 47: 135–141, 2007. doi:10.1016/j.jhep.2007.02.013.
-
(2007)
J Hepatol
, vol.47
, pp. 135-141
-
-
Ekstedt, M.1
Franzén, L.E.2
Mathiesen, U.L.3
Holmqvist, M.4
Bodemar, G.5
Kechagias, S.6
-
15
-
-
84897368255
-
Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
-
Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis Cochrane Database Syst Rev 12: CD008623, 2013. doi:10.1002/14651858.CD008623.pub2.
-
(2013)
Cochrane Database Syst Rev
, vol.12
-
-
Eslami, L.1
Merat, S.2
Malekzadeh, R.3
Nasseri-Moghaddam, S.4
Aramin, H.5
-
16
-
-
84925851378
-
A century of cholesterol and coronaries: From plaques to genes to statins
-
Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell 161: 161–172, 2015. doi:10.1016/j.cell.2015.01.036.
-
(2015)
Cell
, vol.161
, pp. 161-172
-
-
Goldstein, J.L.1
Brown, M.S.2
-
17
-
-
84903187308
-
Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis
-
Granzow M, Schierwagen R, Klein S, Kowallick B, Huss S, Linhart M, Mazar IGR, Görtzen J, Vogt A, Schildberg FA, Gonzalez-Carmona MA, Wojtalla A, Krämer B, Nattermann J, Siegmund SV, Werner N, Fürst DO, Laleman W, Knolle P, Shah VH, Sauerbruch T, Trebicka J. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. Hepatology 60: 334–348, 2014. doi:10.1002/hep.27117.
-
(2014)
Hepatology
, vol.60
, pp. 334-348
-
-
Granzow, M.1
Schierwagen, R.2
Klein, S.3
Kowallick, B.4
Huss, S.5
Linhart, M.6
Mazar, I.7
Görtzen, J.8
Vogt, A.9
Schildberg, F.A.10
Gonzalez-Carmona, M.A.11
Wojtalla, A.12
Krämer, B.13
Nattermann, J.14
Siegmund, S.V.15
Werner, N.16
Fürst, D.O.17
Laleman, W.18
Knolle, P.19
Shah, V.H.20
Sauerbruch, T.21
Trebicka, J.22
more..
-
18
-
-
84991824182
-
Early effects of treatment low-dose atorvastatin on markers of insulin resistance and inflammation in patients with myocardial infarction
-
Gruzdeva O, Uchasova E, Dyleva Y, Akbasheva O, Karetnikova V, Barbarash O. Early effects of treatment low-dose atorvastatin on markers of insulin resistance and inflammation in patients with myocardial infarction. Front Pharmacol 7: 324, 2016. doi:10.3389/fphar.2016.00324.
-
(2016)
Front Pharmacol
, vol.7
, pp. 324
-
-
Gruzdeva, O.1
Uchasova, E.2
Dyleva, Y.3
Akbasheva, O.4
Karetnikova, V.5
Barbarash, O.6
-
19
-
-
84962429880
-
Statin use and survival with early-stage hepatocellular carcinoma
-
Jeon CY, Goodman MT, Cook-Wiens G, Sundaram V. Statin use and survival with early-stage hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 25: 686–692, 2016. doi:10.1158/1055-9965.EPI-15-1040.
-
(2016)
Cancer Epidemiol Biomarkers Prev
, vol.25
, pp. 686-692
-
-
Jeon, C.Y.1
Goodman, M.T.2
Cook-Wiens, G.3
Sundaram, V.4
-
20
-
-
14044265120
-
Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids
-
Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 102: 2561–2566, 2005. doi:10.1073/pnas.0409834102.
-
(2005)
Proc Natl Acad Sci USA
, vol.102
, pp. 2561-2566
-
-
Kapadia, S.B.1
Chisari, F.V.2
-
21
-
-
17744394863
-
Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial
-
Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y, Matsuzawa Y. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 84: 886–891, 2001. doi:10.1054/bjoc.2000.1716.
-
(2001)
Br J Cancer
, vol.84
, pp. 886-891
-
-
Kawata, S.1
Yamasaki, E.2
Nagase, T.3
Inui, Y.4
Ito, N.5
Matsuda, Y.6
Inada, M.7
Tamura, S.8
Noda, S.9
Imai, Y.10
Matsuzawa, Y.11
-
22
-
-
85082452344
-
Statin (3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents
-
Kishta SS, Kishta SA, El-Shenawy R. Statin (3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents. F1000 Res 5: 223, 2016. doi:10.12688/f1000research.7970.2.
-
(2016)
F1000 Res
, vol.5
, pp. 223
-
-
Kishta, S.S.1
Kishta, S.A.2
El-Shenawy, R.3
-
23
-
-
84866858655
-
Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats
-
Klein S, Klösel J, Schierwagen R, Körner C, Granzow M, Huss S, Mazar IGR, Weber S, van den Ven PFM, Pieper-Fürst U, Fürst DO, Nattermann J, Lammert F, Sauerbruch T, Trebicka J. Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. Lab Invest 92: 1440–1450, 2012. doi:10.1038/labinvest.2012.106.
-
(2012)
Lab Invest
, vol.92
, pp. 1440-1450
-
-
Klein, S.1
Klösel, J.2
Schierwagen, R.3
Körner, C.4
Granzow, M.5
Huss, S.6
Mazar, I.7
Weber, S.8
Van Den Ven, P.9
Pieper-Fürst, U.10
Fürst, D.O.11
Nattermann, J.12
Lammert, F.13
Sauerbruch, T.14
Trebicka, J.15
-
24
-
-
0034533147
-
Statins as a newly recognized type of immunomodulator
-
Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 6: 1399–1402, 2000. doi:10.1038/82219.
-
(2000)
Nat Med
, vol.6
, pp. 1399-1402
-
-
Kwak, B.1
Mulhaupt, F.2
Myit, S.3
Mach, F.4
-
25
-
-
36348987648
-
Pravastatin in Chronic Liver Disease Study Investigators. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial
-
Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R; Pravastatin in Chronic Liver Disease Study Investigators. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 46: 1453–1463, 2007. doi:10.1002/hep.21848.
-
(2007)
Hepatology
, vol.46
, pp. 1453-1463
-
-
Lewis, J.H.1
Mortensen, M.E.2
Zweig, S.3
Fusco, M.J.4
Medoff, J.R.5
Belder, R.6
-
26
-
-
84941281919
-
KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: Behind the molecular mechanisms of statins
-
Marrone G, Maeso-Díaz R, García-Cardena G, Abraldes JG, García- Pagán JC, Bosch J, Gracia-Sancho J. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut 64: 1434–1443, 2015. doi:10.1136/gutjnl-2014-308338.
-
(2015)
Gut
, vol.64
, pp. 1434-1443
-
-
Marrone, G.1
Maeso-Díaz, R.2
García-Cardena, G.3
Abraldes, J.G.4
García- Pagán, J.C.5
Bosch, J.6
Gracia-Sancho, J.7
-
27
-
-
84871211218
-
The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins
-
Marrone G, Russo L, Rosado E, Hide D, García-Cardeña G, García- Pagán JC, Bosch J, Gracia-Sancho J. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. J Hepatol 58: 98–103, 2013. doi:10.1016/j.jhep.2012.08.026.
-
(2013)
J Hepatol
, vol.58
, pp. 98-103
-
-
Marrone, G.1
Russo, L.2
Rosado, E.3
Hide, D.4
García-Cardeña, G.5
García- Pagán, J.C.6
Bosch, J.7
Gracia-Sancho, J.8
-
28
-
-
38549149341
-
Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients
-
Martin JE, Cavanaugh TM, Trumbull L, Bass M, Weber F Jr, Aranda-Michel J, Hanaway M, Rudich S. Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients. Clin Transplant 22: 113–119, 2008. doi:10.1111/j.1399-0012.2007.00780.x.
-
(2008)
Clin Transplant
, vol.22
, pp. 113-119
-
-
Martin, J.E.1
Cavanaugh, T.M.2
Trumbull, L.3
Bass, M.4
Weber, F.5
Aranda-Michel, J.6
Hanaway, M.7
Rudich, S.8
-
29
-
-
84888339170
-
Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology
-
Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, Pradere J-P, Schwabe RF. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun 4: 2823, 2013. doi:10.1038/ncomms3823.
-
(2013)
Nat Commun
, vol.4
, pp. 2823
-
-
Mederacke, I.1
Hsu, C.C.2
Troeger, J.S.3
Huebener, P.4
Mu, X.5
Dapito, D.H.6
Pradere, J.-P.7
Schwabe, R.F.8
-
30
-
-
84983567970
-
Simvastatin attenuates liver injury in rodents with biliary cirrhosis submitted to hemorrhage/ resuscitation
-
Meireles CZ, Pasarin M, Lozano JJ, García-Calderó H, Gracia- Sancho J, García-Pagán JC, Bosch J, Abraldes JG. Simvastatin attenuates liver injury in rodents with biliary cirrhosis submitted to hemorrhage/ resuscitation. Shock 47: 370–377, 2017. doi:10.1097/SHK.0000000000000734.
-
(2017)
Shock
, vol.47
, pp. 370-377
-
-
Meireles, C.Z.1
Pasarin, M.2
Lozano, J.J.3
García-Calderó, H.4
Gracia- Sancho, J.5
García-Pagán, J.C.6
Bosch, J.7
Abraldes, J.G.8
-
31
-
-
84959470927
-
Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis
-
Mohanty A, Tate JP, Garcia-Tsao G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis. Gastroenterology 150: 430–40, 2016. doi:10.1053/j.gastro.2015.10.007.
-
(2016)
Gastroenterology
, vol.150
, pp. 430-440
-
-
Mohanty, A.1
Tate, J.P.2
Garcia-Tsao, G.3
-
32
-
-
59449095024
-
Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver
-
Moreno M, Ramalho LN, Sancho-Bru P, Ruiz-Ortega M, Ramalho F, Abraldes JG, Colmenero J, Dominguez M, Egido J, Arroyo V, Ginès P, Bataller R. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. Am J Physiol Gastrointest Liver Physiol 296: G147–G156, 2009. doi:10.1152/ajpgi.00462.2007.
-
(2009)
Am J Physiol Gastrointest Liver Physiol
, vol.296
, pp. G147-G156
-
-
Moreno, M.1
Ramalho, L.N.2
Sancho-Bru, P.3
Ruiz-Ortega, M.4
Ramalho, F.5
Abraldes, J.G.6
Colmenero, J.7
Dominguez, M.8
Egido, J.9
Arroyo, V.10
Ginès, P.11
Bataller, R.12
-
33
-
-
74949102941
-
A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial
-
Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol 43: 990–994, 2009. doi:10.1097/MCG.0b013e31819c392e.
-
(2009)
J Clin Gastroenterol
, vol.43
, pp. 990-994
-
-
Nelson, A.1
Torres, D.M.2
Morgan, A.E.3
Fincke, C.4
Harrison, S.A.5
-
34
-
-
84918802891
-
Atorvastatin treatment improves endothelial function through endothelial progenitor cells mobilization in ischemic heart failure patients
-
Oikonomou E, Siasos G, Zaromitidou M, Hatzis G, Mourouzis K, Chrysohoou C, Zisimos K, Mazaris S, Tourikis P, Athanasiou D, Stefanadis C, Papavassiliou AG, Tousoulis D. Atorvastatin treatment improves endothelial function through endothelial progenitor cells mobilization in ischemic heart failure patients. Atherosclerosis 238: 159–164, 2015. doi:10.1016/j.atherosclerosis.2014.12.014.
-
(2015)
Atherosclerosis
, vol.238
, pp. 159-164
-
-
Oikonomou, E.1
Siasos, G.2
Zaromitidou, M.3
Hatzis, G.4
Mourouzis, K.5
Chrysohoou, C.6
Zisimos, K.7
Mazaris, S.8
Tourikis, P.9
Athanasiou, D.10
Stefanadis, C.11
Papavassiliou, A.G.12
Tousoulis, D.13
-
35
-
-
84982839220
-
Statin drugs decrease progression to cirrhosis in HIV/HCV co-infected individuals
-
August 3
-
Oliver NT, Hartman CM, Kramer JR, Chiao EY. Statin drugs decrease progression to cirrhosis in HIV/HCV co-infected individuals. AIDS (August 3, 2016). doi:10.1097/QAD.0000000000001219.
-
(2016)
AIDS
-
-
Oliver, N.T.1
Hartman, C.M.2
Kramer, J.R.3
Chiao, E.Y.4
-
36
-
-
84865628946
-
Benefits and harms of statin therapy for persons with chronic kidney disease: A systematic review and meta-analysis
-
Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 157: 263–275, 2012. doi:10.7326/0003-4819-157-4-201208210-00007.
-
(2012)
Ann Intern Med
, vol.157
, pp. 263-275
-
-
Palmer, S.C.1
Craig, J.C.2
Navaneethan, S.D.3
Tonelli, M.4
Pellegrini, F.5
Strippoli, G.F.6
-
37
-
-
84919632658
-
The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease
-
Pastori D, Polimeni L, Baratta F, Pani A, Del Ben M, Angelico F. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 47: 4–7, 2015. doi:10.1016/j.dld.2014.07.170.
-
(2015)
Dig Liver Dis
, vol.47
, pp. 4-7
-
-
Pastori, D.1
Polimeni, L.2
Baratta, F.3
Pani, A.4
Del Ben, M.5
Angelico, F.6
-
38
-
-
84863613858
-
Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2
-
Pignatelli P, Carnevale R, Pastori D, Cangemi R, Napoleone L, Bartimoccia S, Nocella C, Basili S, Violi F. Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. Circulation 126: 92–103, 2012. doi:10.1161/CIRCULATIONAHA.112.095554.
-
(2012)
Circulation
, vol.126
, pp. 92-103
-
-
Pignatelli, P.1
Carnevale, R.2
Pastori, D.3
Cangemi, R.4
Napoleone, L.5
Bartimoccia, S.6
Nocella, C.7
Basili, S.8
Violi, F.9
-
39
-
-
84945444881
-
Three months of simvastatin therapy vs. Placebo for severe portal hypertension in cirrhosis: A randomized controlled trial
-
Pollo-Flores P, Soldan M, Santos UC, Kunz DG, Mattos DE, da Silva AC, Marchiori RC, Rezende GFM. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial. Dig Liver Dis 47: 957–963, 2015. doi:10.1016/j.dld.2015.07.156.
-
(2015)
Dig Liver Dis
, vol.47
, pp. 957-963
-
-
Pollo-Flores, P.1
Soldan, M.2
Santos, U.C.3
Kunz, D.G.4
Mattos, D.E.5
Da Silva, A.C.6
Marchiori, R.C.7
Rezende, G.F.M.8
-
40
-
-
79952010116
-
Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK
-
Relja B, Meder F, Wang M, Blaheta R, Henrich D, Marzi I, Lehnert M. Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK. Int J Oncol 38: 879–885, 2011. doi:10.3892/ijo.2010.892.
-
(2011)
Int J Oncol
, vol.38
, pp. 879-885
-
-
Relja, B.1
Meder, F.2
Wang, M.3
Blaheta, R.4
Henrich, D.5
Marzi, I.6
Lehnert, M.7
-
41
-
-
85009471306
-
A nitric oxide-donating statin decreases portal pressure with a better toxicity profile than conventional statins in cirrhotic rats
-
Rodríguez S, Raurell I, Torres-Arauz M, García-Lezana T, Genescà J, Martell M. A nitric oxide-donating statin decreases portal pressure with a better toxicity profile than conventional statins in cirrhotic rats. Sci Rep 7: 40461, 2017. doi:10.1038/srep40461.
-
(2017)
Sci Rep
, vol.7
, pp. 40461
-
-
Rodríguez, S.1
Raurell, I.2
Torres-Arauz, M.3
García-Lezana, T.4
Genescà, J.5
Martell, M.6
-
42
-
-
84904698842
-
Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network
-
Russo MW, Hoofnagle JH, Gu J, Fontana RJ, Barnhart H, Kleiner DE, Chalasani N, Bonkovsky HL. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology 60: 679–686, 2014. doi:10.1002/hep.27157.
-
(2014)
Hepatology
, vol.60
, pp. 679-686
-
-
Russo, M.W.1
Hoofnagle, J.H.2
Gu, J.3
Fontana, R.J.4
Barnhart, H.5
Kleiner, D.E.6
Chalasani, N.7
Bonkovsky, H.L.8
-
43
-
-
70449096299
-
Drug-induced liver injury associated with statins
-
Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis 29: 412–422, 2009. doi:10.1055/s-0029-1240010.
-
(2009)
Semin Liver Dis
, vol.29
, pp. 412-422
-
-
Russo, M.W.1
Scobey, M.2
Bonkovsky, H.L.3
-
44
-
-
84990998378
-
Statins improve NASH via inhibition of RhoA and Ras
-
Schierwagen R, Maybüchen L, Hittatiya K, Klein S, Uschner FE, Braga TT, Franklin BS, Nickenig G, Strassburg CP, Plat J, Sauerbruch T, Latz E, Lütjohann D, Zimmer S, Trebicka J. Statins improve NASH via inhibition of RhoA and Ras. Am J Physiol Gastrointest Liver Physiol 311: G724–G733, 2016. doi:10.1152/ajpgi.00063.2016.
-
(2016)
Am J Physiol Gastrointest Liver Physiol
, vol.311
, pp. G724-G733
-
-
Schierwagen, R.1
Maybüchen, L.2
Hittatiya, K.3
Klein, S.4
Uschner, F.E.5
Braga, T.T.6
Franklin, B.S.7
Nickenig, G.8
Strassburg, C.P.9
Plat, J.10
Sauerbruch, T.11
Latz, E.12
Lütjohann, D.13
Zimmer, S.14
Trebicka, J.15
-
45
-
-
84976491135
-
Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES
-
Simon TG, Bonilla H, Yan P, Chung RT, Butt AA. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatology 64: 47–57, 2016. doi:10.1002/hep.28506.
-
(2016)
Hepatology
, vol.64
, pp. 47-57
-
-
Simon, T.G.1
Bonilla, H.2
Yan, P.3
Chung, R.T.4
Butt, A.A.5
-
46
-
-
84881491358
-
Statins are associated with a reduced risk of hepatocellular cancer: A systematic review and meta-analysis
-
Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 144: 323–332, 2013. doi:10.1053/j.gastro.2012.10.005.
-
(2013)
Gastroenterology
, vol.144
, pp. 323-332
-
-
Singh, S.1
Singh, P.P.2
Singh, A.G.3
Murad, M.H.4
Sanchez, W.5
-
47
-
-
77049089696
-
Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment
-
Stojakovic T, Claudel T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Sourij H, Stauber RE, Winkler K, März W, Wascher TC, Trauner M. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis 209: 178–183, 2010. doi:10.1016/j. atherosclerosis.2009.08.052.
-
(2010)
Atherosclerosis
, vol.209
, pp. 178-183
-
-
Stojakovic, T.1
Claudel, T.2
Putz-Bankuti, C.3
Fauler, G.4
Scharnagl, H.5
Wagner, M.6
Sourij, H.7
Stauber, R.E.8
Winkler, K.9
März, W.10
Wascher, T.C.11
Trauner, M.12
-
48
-
-
34548758431
-
Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid
-
Stojakovic T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Stadlbauer V, Gurakuqi G, Stauber RE, März W, Trauner M. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 46: 776–784, 2007. doi:10.1002/hep.21741.
-
(2007)
Hepatology
, vol.46
, pp. 776-784
-
-
Stojakovic, T.1
Putz-Bankuti, C.2
Fauler, G.3
Scharnagl, H.4
Wagner, M.5
Stadlbauer, V.6
Gurakuqi, G.7
Stauber, R.E.8
März, W.9
Trauner, M.10
-
49
-
-
34547469050
-
Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase
-
Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, Nevens F, Sauerbruch T, Heller J. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 46: 242–253, 2007. doi:10.1002/hep.21673.
-
(2007)
Hepatology
, vol.46
, pp. 242-253
-
-
Trebicka, J.1
Hennenberg, M.2
Laleman, W.3
Shelest, N.4
Biecker, E.5
Schepke, M.6
Nevens, F.7
Sauerbruch, T.8
Heller, J.9
-
50
-
-
77956268976
-
Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells
-
Trebicka J, Hennenberg M, Odenthal M, Shir K, Klein S, Granzow M, Vogt A, Dienes H-P, Lammert F, Reichen J, Heller J, Sauerbruch T. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 53: 702–712, 2010. doi:10.1016/j.jhep.2010.04.025.
-
(2010)
J Hepatol
, vol.53
, pp. 702-712
-
-
Trebicka, J.1
Hennenberg, M.2
Odenthal, M.3
Shir, K.4
Klein, S.5
Granzow, M.6
Vogt, A.7
Dienes, H.-P.8
Lammert, F.9
Reichen, J.10
Heller, J.11
Sauerbruch, T.12
-
51
-
-
84921385810
-
Etiology and Complications of Portal Vein Thrombosis
-
Trebicka J, Strassburg CP. Etiology and Complications of Portal Vein Thrombosis. Viszeralmedizin 30: 375–380, 2014. doi:10.1159/000369987.
-
(2014)
Viszeralmedizin
, vol.30
, pp. 375-380
-
-
Trebicka, J.1
Strassburg, C.P.2
-
53
-
-
84942436651
-
Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension
-
Uschner FE, Ranabhat G, Choi SS, Granzow M, Klein S, Schierwagen R, Raskopf E, Gautsch S, van der Ven PF, Fürst DO, Strassburg CP, Sauerbruch T, Diehl AM, Trebicka J. Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. Sci Rep 5: 14573, 2015. doi:10.1038/srep14573.
-
(2015)
Sci Rep
, vol.5
, pp. 14573
-
-
Uschner, F.E.1
Ranabhat, G.2
Choi, S.S.3
Granzow, M.4
Klein, S.5
Schierwagen, R.6
Raskopf, E.7
Gautsch, S.8
van der Ven, P.F.9
Fürst, D.O.10
Strassburg, C.P.11
Sauerbruch, T.12
Diehl, A.M.13
Trebicka, J.14
-
54
-
-
84945437158
-
Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection
-
Yang YH, Chen WC, Tsan YT, Chen MJ, Shih WT, Tsai YH, Chen PC. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. J Hepatol 63: 1111–1117, 2015. doi:10.1016/j.jhep.2015.07.006.
-
(2015)
J Hepatol
, vol.63
, pp. 1111-1117
-
-
Yang, Y.H.1
Chen, W.C.2
Tsan, Y.T.3
Chen, M.J.4
Shih, W.T.5
Tsai, Y.H.6
Chen, P.C.7
-
55
-
-
33747810129
-
Intrahepatic upregulation of RhoA and Rhokinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis
-
Zhou Q, Hennenberg M, Trebicka J, Jochem K, Leifeld L, Biecker E, Sauerbruch T, Heller J. Intrahepatic upregulation of RhoA and Rhokinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 55: 1296–1305, 2006. doi:10.1136/gut.2005.081059.
-
(2006)
Gut
, vol.55
, pp. 1296-1305
-
-
Zhou, Q.1
Hennenberg, M.2
Trebicka, J.3
Jochem, K.4
Leifeld, L.5
Biecker, E.6
Sauerbruch, T.7
Heller, J.8
|